rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CLDX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results
      Nov 10Yahoo FinanceCLDX
      Celldex at guggenheim conference: barzolvolimab nears launch
      Nov 9Investing.comCLDX
      Celldex Stock In Focus After Earnings Loss And Shelf Filing

      Celldex Therapeutics reported third quarter 2026 results with a net loss of US$75.56 million and basic loss per share of US$0.96, alongside a universal shelf registration covering common and preferred stock, warrants, depositary shares and units. The combination of widening losses and a fresh universal shelf registration highlights the pressure on Celldex Therapeutics to secure funding while it continues to invest heavily in its antibody pipeline without meaningful current revenue. We will...

      Nov 6Yahoo FinanceCLDX
      Celldex: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceCLDX
      Celldex to Present at Upcoming Investor Conferences
      Nov 4Yahoo FinanceCLDX
      Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation

      Celldex Therapeutics has seen a mixed share price story in recent years, and that uneven record puts the spotlight on whether the current market value still lines up with what its balance sheet supports. With fresh shareholder litigation headlines now in the mix, the question for you is how much of today’s price rests on expectations that sit beyond the company’s book value. Over the past 5 years the stock has fallen 41.9%, which puts long term holders squarely on the issue of whether the...

      Oct 17Yahoo FinanceCLDX
      Celldex Therapeutics: Trying To Put Its Troubled History Behind It (NASDAQ:CLDX)

      Celldex's recent Phase 3 barzolvolimab trials in chronic spontaneous urticaria met endpoints, but the market reaction was negative. Read more on CLDX stock here.

      Oct 7Seeking AlphaCLDX
      Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX)

      Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCLDX
      Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings
      Sep 23Investing.comCLDX
      Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
      Sep 23Yahoo FinanceCLDX
      The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

      Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

      Sep 23Yahoo FinanceCLDXKODPCVX
      Morgan Stanley raises Celldex Therapeutics price target on urticaria drug progress
      Sep 23Investing.comCLDX
      Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CLDX) 2026-09-22
      Sep 22Seeking AlphaCLDX
      Why is Celldex Therapeutics stock sliding today?
      Sep 22Investing.comCLDX
      Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Celldex Therapeutics (NASDAQ:CLDX)

      Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.

      Sep 22BenzingaCLDX
      Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

      Celldex Therapeutics (NASDAQ:CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the pr

      Sep 22Yahoo FinanceCLDX
      Stifel reiterates Celldex Therapeutics stock Buy rating after trial data
      Sep 22Investing.comCLDX
      Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials

      Celldex Therapeutics (NASDAQ:CLDX) shares gained 8% on Tuesday after the company reported positive topline results from two Phase 3 trials evaluating barzolvolimab in patients with chronic spontaneous urticaria (CSU). Both EMBARQ-CSU1 and EMBARQ-CSU2 met their primary endpoints and all key secondary endpoints, demonstrating statistically significant improvements in disease activity compared with placebo.

      Sep 22Yahoo FinanceCLDX
      Celldex stock falls after hives trial data (CLDX:NASDAQ)

      Celldex (CLDX) stock sank after the company posted Phase 3 trial data for its hives therapy. Read more here.

      Sep 22Seeking AlphaCLDX
      Why is Celldex Therapeutics stock plummeting today?
      Sep 22Investing.comCLDX
      Celldex reports positive phase 3 trial results for CSU drug
      Sep 22Investing.comCLDX
      Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials

      Celldex Therapeutics' (CLDX) two Phase 3 trials of barzolvolimab in patients with chronic spontaneou

      Sep 22Yahoo FinanceCLDX
      Celldex stock rises after positive phase 3 trial results
      Sep 22Investing.comCLDX
      CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
      Sep 22Yahoo FinanceCLDX
      Celldex at Cantor conference: barzolvolimab data loom
      Sep 10Investing.comCLDX
      Celldex to Present at Upcoming Investor Conference

      HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET. The webcast of the presentation will be available on the “Events and Presentations” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver

      Sep 8Yahoo FinanceCLDX

      This is the newest page. Registered accounts read further back.